Results: 1-25 | 26-36
Results: 1-25/36

Authors: Brekke, MK Lieberman, R Wright, E Green, DR
Citation: Mk. Brekke et al., Posterior facet talocalcaneal coalition, J AM POD M, 91(8), 2001, pp. 422-426

Authors: Liu, YQ Kyle, E Patel, S Housseau, F Hakim, F Lieberman, R Pins, M Blagosklonny, MV Bergan, RC
Citation: Yq. Liu et al., Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells, PROSTATE C, 4(2), 2001, pp. 81-91

Authors: Geske, FJ Lieberman, R Strange, R Gerschenson, LE
Citation: Fj. Geske et al., Early stages of p53-induced apoptosis are reversible, CELL DEAT D, 8(2), 2001, pp. 182-191

Authors: Menter, DG Hoque, A Motiwala, N Sahin, AA Sneige, N Lieberman, R Lippman, SM
Citation: Dg. Menter et al., Computerized image analysis of Ki-67 in ductal breast carcinoma in situ, ANAL QUAN C, 23(3), 2001, pp. 218-228

Authors: Carroll, PR Fair, WR Grossfeld, GD Heston, WDW Lieberman, R Malkowicz, SB Stricker, HJ Sylvester, J Peehl, DM Meyer, F Hart, C
Citation: Pr. Carroll et al., Overview consensus statement, UROLOGY, 58(2A), 2001, pp. 1-4

Authors: Fair, WR Stricker, HJ Lieberman, R Bubley, GJ Trachtenberg, J Heston, WDW
Citation: Wr. Fair et al., Discussion following Dr. Hans J. Stricker's presentations, UROLOGY, 58(2A), 2001, pp. 27-27

Authors: Lieberman, R Gleave, ME Carroll, PR Bubley, GJ
Citation: R. Lieberman et al., Discussion following Dr. Martin E. Gleave's presentation, UROLOGY, 58(2A), 2001, pp. 48-49

Authors: Lieberman, R
Citation: R. Lieberman, Androgen deprivation therapy for prostate cancer chemoprevention: Current status and future directions for agent development, UROLOGY, 58(2A), 2001, pp. 83-90

Authors: Lieberman, R Lubeck, DP Trachtenberg, J Stricker, HJ Newling, DWW Fair, WR Carroll, PR
Citation: R. Lieberman et al., The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer - Discussion, UROLOGY, 58(2A), 2001, pp. 99-100

Authors: Newling, DWW Daniell, HW Lieberman, R Sylvester, J Trachtenberg, J
Citation: Dww. Newling et al., Osteoporosis due to androgen deprivation therapy in men with prostate cancer - Discussion, UROLOGY, 58(2A), 2001, pp. 106-107

Authors: Lieberman, R Nelson, WG
Citation: R. Lieberman et Wg. Nelson, New clinical trial strategies for prostate cancer prevention - Introduction, UROLOGY, 57(4A), 2001, pp. 1-3

Authors: Lieberman, R Nelson, WG Sakr, WA Meysken, FL Klein, EA Wilding, G Partin, AW Lee, JJ Lippman, SM
Citation: R. Lieberman et al., Executive summary of the National Cancer Institute Workshop: Highlights and recommendations, UROLOGY, 57(4A), 2001, pp. 4-27

Authors: Kelloff, GJ Lieberman, R Seele, VE Boone, CM Lubet, RA Kopelovich, L Malone, WA Crowell, JA Higley, HR Sigman, CC
Citation: Gj. Kelloff et al., Acents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer, UROLOGY, 57(4A), 2001, pp. 46-51

Authors: Boone, CW Lieberman, R Mairinger, T Palcic, B Bacus, J Bartels, P
Citation: Cw. Boone et al., Computer-assisted image analysis-derived intermediate endpoints, UROLOGY, 57(4A), 2001, pp. 129-131

Authors: Lopacznski, W Hruszkewycz, AM Lieberman, R
Citation: W. Lopacznski et al., Preprostatectomy: A clinical model to study stromal-epithelial interactions, UROLOGY, 57(4A), 2001, pp. 194-199

Authors: Lee, JD Lieberman, R Sloan, JA Piantadosi, S Lippman, SM
Citation: Jd. Lee et al., Design considerations for efficient prostate cancer chemoprevention trials, UROLOGY, 57(4A), 2001, pp. 205-212

Authors: Weiss, HL Urban, DA Grizzle, WE Cronin, KA Freedman, LS Kelloff, GJ Lieberman, R
Citation: Hl. Weiss et al., Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancer, UROLOGY, 57(4A), 2001, pp. 220-223

Authors: Lieberman, R
Citation: R. Lieberman, Prostate cancer chemoprevention: Strategies for designing efficient clinical trials, UROLOGY, 57(4A), 2001, pp. 224-229

Authors: Lieberman, R
Citation: R. Lieberman, Chemoprevention of superficial bladder cancer, CANC TREAT, 2001, pp. 237-254

Authors: Greenwald, P Lieberman, R
Citation: P. Greenwald et R. Lieberman, Chemoprevention trials for prostate cancer, CONT CANC R, 2001, pp. 499-518

Authors: Lieberman, R
Citation: R. Lieberman, HIV in older Americans: An epidemiologic perspective, J MIDWIFE W, 45(2), 2000, pp. 176-182

Authors: Geske, FJ Nelson, AC Lieberman, R Strange, R Sun, T Gerschenson, LE
Citation: Fj. Geske et al., DNA repair is activated in early stages of p53-induced apoptosis, CELL DEAT D, 7(4), 2000, pp. 393-401

Authors: Singletary, E Lieberman, R Atkinson, N Sneige, N Sahin, A Tolley, S Colchin, M Bevers, T Stelling, C Fornage, B Fritsche, H Hittelman, W Kelloff, G Lippman, SM
Citation: E. Singletary et al., Novel translational model for breast cancer chemoprevention study: Accrualto a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide, CANC EPID B, 9(10), 2000, pp. 1087-1090

Authors: Liu, YQ Kyle, E Lieberman, R Crowell, J Kelloff, G Bergan, RC
Citation: Yq. Liu et al., Focal adhesion kinase (FAK) phosphorylation is not required for genistein-induced FAK-beta-1-integrin complex formation, CLIN EXP M, 18(3), 2000, pp. 203-212

Authors: Kelloff, GJ Crowell, JA Steele, VE Lubet, RA Malone, WA Boone, CW Kopelovich, L Hawk, ET Lieberman, R Lawrence, JA Ali, I Viner, JL Sigman, CC
Citation: Gj. Kelloff et al., Progress in cancer chemoprevention: Development of diet-derived chemopreventive agents, J NUTR, 130(2), 2000, pp. 467S-471S
Risultati: 1-25 | 26-36